New FFG Grant

We are delighted to share that our company has been selected to receive a grant from the Austrian Lifesciences Programme, a prestigious initiative administered by the Austrian Research Promotion Agency. This grant is a testament to the innovative work we are doing in the field of life sciences and will help us to continue pushing the boundaries of scientific research and development. With the support of the Austrian Life Sciences Programme, we can accelerate our efforts on our ground-breaking ideas.

Our Presentation at EuroPCR 2023

We are excited to announce that our company will not only participate in EuroPCR 2023, but we will also be giving a presentation at the conference! This is a fantastic opportunity for us to showcase our latest research and innovation.
EuroPCR is one of the largest and most prestigious conferences in the field of cardiology, and we are honored to be a part of it.
We invite you to join us at EuroPCR 2023 to learn more about our innovative implant and hear our presentation.

Presentation at Transcatheter Cardiovascular Therapeutics (TCT) Conference in Boston

We are excited to announce that AVVie will be attending TCT 2022 Boston.

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation’s (CRF) annual scientific symposium. The world’s foremost educational forum specializing in interventional cardiovascular medicine will be held on September 16-19, 2022, at Boston Convention and Exhibition Center.

Dr. Mathew R. Williams will present our technology and latest achievements on September 18th in TCT Innovation: Transcatheter Mitral Valve Technologies session.

AVVie Awarded EU Seal of Excellence

AVVie was recently given the Seal of Excellence by the European Commission, a prestigious recognition for superior, innovative concepts deserving financial support. With this award, the European Commission affirms AVVie as a highly innovative company that can successfully compete globally in fast-growing areas.

The Seal of Excellence is a high-quality certificate given to projects submitted to the Horizon Program that have met all the strict selection and award requirements but were unable to get funding because of budgetary restrictions. The „Seal“ proves that the AVVie has commercial value and justifies support from different sources, whether public, private, national, regional, European, or global.

For more information about the Seal of Excellence, visit

Presentation at CRT Meeting in Washington

Prof. Mohl, founder of AVVie, recently presented at the 2020 CRT Conference in Washington.
CRT, one of the world’s leading interventional cardiology conferences organized by Cardiovascular Research Technologies (CRT) Group Foundation, took place on February 22 – 25 2020. On February 24th, Prof. Mohl gave his presentation entitled „Percutaneous mitral valve repair with artificial papillary muscle“.

On the same day, AVVie’s chairman was interviewed for Cardiotube. To watch the whole discussion, please visit: httpss://

AVVie wins S&B (Science and Business)

This year AVVie has been chosen to be among the 10 best start-ups and had the opportunity to take part in the S&B Award competition. The S&B (Science and Business)-Award granted by Rudolf Sallinger Fonds awards scientific entrepreneurs.

The Mitral Butterfly competed with other 9 great projects and each one of them was a strong competitor. AVVie representatives, together with Prof. Mohl presented the innovative idea in front of a professional jury and awaited the verdict.

At the gala on 19th of June, AVVie was announced to be a winner of S&B Award 2019. AVVie won the competition and was awarded with a 20.000 € price.

Mitral Butterfly shortlisted at EACTS

Mitral Butterfly shortlisted at EACTS Techno-College Innovation Award.

An abstract on AVVie’s technology has been shortlisted as one of five finalists at the EACTS Techno-College Innovation Award. Professor Werner Mohl presented the Mitral Butterfly implant in front of a judging panel and assembled audience in a rapid response format on October 20thas part of the Lion’s Den session in Milano.

An Update is presented at the PCR London Valves 2018

An Update of the Mitral Butterfly technology is presented at the PCR London Valves 2018

In June of 2018, Prof. Werner Mohl MD, PhD, was asked to present an update on the Angel Valve Mitral Butterfly implant at the prestigious PCR London Valves 2018 Innovator’s Day on September 9th.  The presentation is included in the „Emerging Mitral Devices“ section of the program.

PCR London Valves Innovator’s Day 2017

Johanna Ticar presented the results of Mitral Butterfly®´s first in vitro tests at 2017 PCR London Valves Innovator´s Day. The three day international conference brought over 2000 interventional cardiologists as well as representatives of the cardiovascular device industry together to discuss the latest trends in the field.


tct2016: Transvascular repair of mitral valve prolapse: The Mitral Butterfly

Werner Mohl, MD,PhD

A step ahead in Transcatheter mitral valve repair